Health
BAT’s COVID-19 vaccine candidate gets FDA approval for human study – Reuters
British American Tobacco, the maker of Dunhill and Lucky Strike cigarettes, said on Wednesday its COVID-19 vaccine candidate was approved by the U.S. Food and Drug…
By Reuters Staff
Dec 16 (Reuters) – British American Tobacco, the maker of Dunhill and Lucky Strike cigarettes, said on Wednesday its COVID-19 vaccine candidate was approved by the U.S. Food and Drug Administration for Phase I human study.
The Worlds No.2 cigarette company had earlier this year said it was working on a COVID-19 vaccine using proteins extracted from tobacco leaves.
The company said the enrolment for the study is expected to begin shortly.
-
Noosa News14 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News14 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots
-
Business18 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business17 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025